165 related articles for article (PubMed ID: 8702757)
1. The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity.
Tian Y; Wu LH; Oxender DL; Chung FZ
J Biol Chem; 1996 Aug; 271(34):20250-7. PubMed ID: 8702757
[TBL] [Abstract][Full Text] [Related]
2. Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists.
Gether U; Johansen TE; Schwartz TW
J Biol Chem; 1993 Apr; 268(11):7893-8. PubMed ID: 7681831
[TBL] [Abstract][Full Text] [Related]
3. Contractile effect of tachykinins on Suncus murinus (house musk shrew) isolated ileum.
Cheng FH; Chan SW; Rudd JA
Neuropeptides; 2008; 42(5-6):671-9. PubMed ID: 18582934
[TBL] [Abstract][Full Text] [Related]
4. Structural motifs encoded by individual exons of the human neurokinin-1 receptor gene interact differentially with selective agonists and antagonists.
Tian Y; Wu LH; Pu Y; Huang CC; Chung FZ
J Neurochem; 1996 Sep; 67(3):1191-9. PubMed ID: 8752126
[TBL] [Abstract][Full Text] [Related]
5. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly in NK1 receptors in guinea pig lung.
Geraghty DP; Mussap CJ; Burcher E
Mol Pharmacol; 1992 Jan; 41(1):147-53. PubMed ID: 1370705
[TBL] [Abstract][Full Text] [Related]
6. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
7. Neurokinin release in the rat nucleus of the solitary tract via NMDA and AMPA receptors.
Colin I; Blondeau C; Baude A
Neuroscience; 2002; 115(4):1023-33. PubMed ID: 12453476
[TBL] [Abstract][Full Text] [Related]
8. Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors.
Cascieri MA; Huang RR; Fong TM; Cheung AH; Sadowski S; Ber E; Strader CD
Mol Pharmacol; 1992 Jun; 41(6):1096-9. PubMed ID: 1377326
[TBL] [Abstract][Full Text] [Related]
9. Novel selective agonists and antagonists confirm neurokinin NK1 receptors in guinea-pig vas deferens.
Hall JM; Morton IK
Br J Pharmacol; 1991 Feb; 102(2):511-7. PubMed ID: 1707714
[TBL] [Abstract][Full Text] [Related]
10. Central tachykinin NK3 receptors in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII.
Broccardo M; Improta G; Tabacco A
Eur J Pharmacol; 1999 Jul; 376(1-2):67-71. PubMed ID: 10440091
[TBL] [Abstract][Full Text] [Related]
11. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of tachykinin NK3 receptor-mediated colonic ion transport in the guinea pig.
Goldhill J; Angel I
Eur J Pharmacol; 1998 Dec; 363(2-3):161-8. PubMed ID: 9881585
[TBL] [Abstract][Full Text] [Related]
13. Identification in the NK1 tachykinin receptor of a domain involved in recognition of neurokinin A and septide but not of substance P.
Wijkhuisen A; Sagot MA; Frobert Y; Créminon C; Grassi J; Boquet D; Couraud JY
FEBS Lett; 1999 Mar; 447(2-3):155-9. PubMed ID: 10214937
[TBL] [Abstract][Full Text] [Related]
14. Substance P(6-11) and natural tachykinins interact with septide-sensitive tachykinin receptors coupled to a phospholipase C in the rat urinary bladder.
Torrens Y; Saffroy M; Glowinski J; Beaujouan JC
Neuropeptides; 1997 Jun; 31(3):243-51. PubMed ID: 9243521
[TBL] [Abstract][Full Text] [Related]
15. Effect of scyliorhinin I and synthetic scyliorhinin I derivatives at mammalian tachykinin NK1, NK2 and NK3 receptors.
Patacchini R; Quartara L; Rolka K; Zboinska J; Kupryszewski G; Maggi CA
Eur J Pharmacol; 1993 Dec; 250(2):311-6. PubMed ID: 7509285
[TBL] [Abstract][Full Text] [Related]
16. Tachykinin receptors in the guinea-pig renal pelvis: activation by exogenous and endogenous tachykinins.
Maggi CA; Patacchini R; Eglezos A; Quartara L; Giuliani S; Giachetti A
Br J Pharmacol; 1992 Sep; 107(1):27-33. PubMed ID: 1384907
[TBL] [Abstract][Full Text] [Related]
17. Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.
Gether U; Yokota Y; Emonds-Alt X; Brelière JC; Lowe JA; Snider RM; Nakanishi S; Schwartz TW
Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6194-8. PubMed ID: 7687062
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist.
Gitter BD; Waters DC; Threlkeld PG; Lovelace AM; Matsumoto K; Bruns RF
Eur J Pharmacol; 1995 May; 289(3):439-46. PubMed ID: 7556412
[TBL] [Abstract][Full Text] [Related]
19. Tachykinins in the gut. Part I. Expression, release and motor function.
Holzer P; Holzer-Petsche U
Pharmacol Ther; 1997; 73(3):173-217. PubMed ID: 9175155
[TBL] [Abstract][Full Text] [Related]
20. A new selective bioassay for tachykinin NK3 receptors based on inositol monophosphate accumulation in the guinea pig ileum.
Petitet F; Saffroy M; Torrens Y; Glowinski J; Beaujouan JC
Eur J Pharmacol; 1993 Oct; 247(2):185-91. PubMed ID: 7506659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
